Thomas Okarma, MD, PhD, is president and chief executive officer of Geron Corporation. After receiving his PhD and MD degrees at Stanford University, Dr. Okarma became a member of the faculty in the Department of Medicine at Stanford University School of Medicine in 1980. Dr. Okarma left Stanford in 1985 and founded Applied Immune Sciences, Inc. (AIS) where he was chief executive officer. By the time of its acquisition by Rhone-Poulenc Rorer in 1995, AIS was in advanced cell therapy human clinical trials in cancer and bone marrow transplantation and in early gene therapy human trials in breast cancer.
David A. Prentice, PhD, is professor of life sciences at Indiana State University, adjunct professor of Medical and Molecular Genetics for Indiana University School of Medicine, and a founding member of Do No Harm: The Coalition of Americans for Research Ethics, an organization dedicated to the promotion of scientific research and health care that does no harm to human life. One current focus of his research is on adult stem cells and their differentiation signals.
Arti Rai, JD, is assistant professor of law at the University of Pennsylvania School of Law. She attended Harvard Medical School prior to receiving her law degree from Harvard Law School. Professor Rai teaches and writes in the areas of biotechnology and the law, patent law, and health care regulation. Her recent work addresses the interaction between the public and private sectors in biomedical research. She is a co-author of Law and the Mental Health System (West Publishing) and serves on the Board of Editors of the American Journal of Law and Medicine.
Jay Siegel, MD, is director of the Office of Therapeutics Research and Review (OTRR) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA). His office has responsibility for regulation of biological therapeutics, including cell therapies, gene therapies, monoclonal antibodies, cytokines, and other proteins. This office has over a decade of experience in applications review,